U.S. License Holder:
Daiichi Sankyo
Date of License:
December-20-2019
Last Update:
January-08-2021
FDA-Approved Indications
ENHERTU (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.